Draft $2,400 Manufacturing Readiness Assessment for CYTROGEN via FOIA Intelligence
- Organization
- NSF SBIR Phase I funding structure (research capital without commercial manufacturing knowledge)
- Sector
- CYTROGEN (specifically) needing manufacturing scale-up expertise for Phase II preparation
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Market catalyst
CYTROGEN has $305K SBIR funding for technical research but zero manufacturing expertise or connections. Academic researchers lack knowledge of GMP requirements, FDA Quality System Regulations, and qualified contract manufacturers - creating a knowledge gap between lab synthesis and commercial production.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.